OurView’s promise of “No contracts” and cancellation at any time sounds straightforward until it meets the separate rules for prepaid treatment and shipped prescriptions. The platform offers monthly payments or three-month prepayment for compounded GLP-1 medications, while its return policy makes sales final after payment has been charged and a package handed to the carrier. For someone considering enrollment, the central question is not simply whether cancellation is allowed, but what cancellation stops—and what money, if any, remains refundable.
This review examines OurView’s public documentation consulted October 19, 2026, with particular attention to those boundaries. OurView documents real offerings, prices, a patient portal and order-support contacts. It also expressly separates its platform role from medical and pharmacy services. Less clear are automatic renewal mechanics, the disposition of unused quarterly prepayments and refunds when no prescription is issued. Those gaps do not establish that the service lacks workable procedures; they mean prospective patients should obtain the applicable procedures before paying.
At a glance
- Service structure
- OurView describes itself as a patient-management platform partnering with independent physician networks and a licensed U.S. pharmacy, not as the direct medical or pharmacy provider.Sources: [4]
- Compounded semaglutide price
- $109 monthly or $297 prepaid for three months, equivalent to $99 per month. The offer says any prescribed dose, no membership fee and free shipping.Sources: [4]
- Compounded tirzepatide price
- $129 monthly or $357 prepaid for three months, equivalent to $119 per month. The offer says any prescribed dose, no membership fee and free shipping.Sources: [4]
- Cancellation boundary
- The policy directs patients to the portal to cancel before products ship; it separately makes sales final once payment is charged and the package is handed to the carrier.Sources: [3]
- Insurance restriction
- The terms say the service is not insurance and prohibit submitting claims for its telemedicine services to Medicare or other federal, state or private payers.Sources: [5]
Start with the exit terms, not the enrollment slogan
OurView’s weight-loss page advertises “Cancel anytime” and says patients are not locked in. Its operational instructions are more specific: patients can log into patient.ourviewhealth.com before products ship to cancel a subscription or change an address or payment method. That is a documented cancellation route, but the consulted policy does not establish a numerical advance-notice deadline, the next billing date or how quickly a portal request changes an order already being prepared.
A separate provision says all sales are final once the payment method has been charged and the package handed to USPS, FedEx or UPS. This is not the same as saying cancellation always produces a refund. Nor does it clearly promise a refund for every cancellation made before carrier handoff. The most consequential unresolved issue is how cancellation affects the unused portion of a three-month prepayment, particularly if medication is dispensed or shipped in stages.
Before paying, ask OurView to distinguish stopping future renewals from canceling an existing pharmacy order and recovering unused prepaid funds. Keep the answer with the receipt and order status. Our guide to cancellation notice and order status explains why those are separate questions. Here, “No contracts” is best read as a marketing description of flexibility, not as evidence that the published terms and payment conditions disappear.
Two payment choices, with different amounts at stake
The advertised semaglutide offering is compounded medication at $109 monthly or $297 prepaid for three months. Tirzepatide is likewise compounded, at $129 monthly or $357 prepaid for three months. The lower $99 and $119 monthly equivalents require quarterly prepayment; they are not standalone monthly payment options. OurView advertises a $30 saving on each three-month plan. Monthly payment remains an alternative, rather than a requirement to pay three months upfront.
Both offers say “Any prescribed dose,” no membership fee and free shipping. That supports a claim that the listed price does not rise with the prescribed dose under the advertised offer; it does not establish a permanent price lock. The terms also reserve a response to inaccurate posted prices: accept the corrected price or forgo the transaction. No separate introductory-versus-renewal schedule appears in the consulted documentation, and future billing mechanics remain insufficiently described.
The commercial descriptions do not establish the exact route, concentration, presentation, quantity dispensed or included administration supplies. A three-month package label alone does not answer those product questions or establish a minimum treatment commitment. Ask for an itemized quote tied to the actual prescription and payment schedule. Our explanation of monthly prices and billing commitments provides a framework for separating the displayed monthly equivalent from the amount collected.
| Option or term | Documented amount or condition | What to clarify |
|---|---|---|
| Compounded semaglutide, monthly | $109 per month; any prescribed dose | Next charge date and renewal procedure |
| Compounded semaglutide, quarterly | $297 prepaid for three months; $99 monthly equivalent | Treatment of unused prepayment after cancellation |
| Compounded tirzepatide, monthly | $129 per month; any prescribed dose | Next charge date and renewal procedure |
| Compounded tirzepatide, quarterly | $357 prepaid for three months; $119 monthly equivalent | Dispensing schedule and unused-payment policy |
| Both advertised medication offers | No membership fee; free shipping | Exact formulation, presentation, supplies and other possible charges |
A free assessment is not a prescription guarantee
OurView invites users to complete a free assessment with “No commitment. No contracts.” The advertised journey involves answering health and treatment questions, followed by a licensed provider’s eligibility review and treatment-plan decision. Its claim that getting started takes about three minutes describes entry into that process. It is not a documented deadline for clinical approval, prescription preparation or medication arrival, and the public pages do not provide numerical turnaround guarantees for those steps.
The payment disclaimer is unusually important to read before selecting a plan: payment does not guarantee that a prescription will be written or dispensed. The terms also allow a provider to deny care when professional judgment finds it medically or ethically inappropriate, including potential misuse. What the consulted policies do not explain is the financial outcome if payment has already been collected and the clinician declines treatment or no medication is dispensed.
The site’s terms require users to be at least 18, while also addressing a parent or guardian’s responsibility when using the site for a minor. That language does not establish pediatric GLP-1 eligibility. Services are restricted to residents of the United States and its territories, but no state-by-state availability list was established. Complete clinical criteria, laboratory requirements and exclusions were also unavailable, so geographic access and clinical acceptance both require confirmation rather than inference.
The platform, clinician and pharmacy have different jobs
OurView identifies itself as a patient-management platform that partners with independent licensed physician networks and a licensed U.S. pharmacy. It says it does not directly provide medical or pharmacy services and is not a state-licensed pharmacy or drug manufacturer. Its commercial explanation attributes pricing to a direct relationship with a pharmacy it describes as nationwide, which compounds and dispenses medication. These are provider statements, not independent verification of licenses or nationwide clinical availability.
The consulted pages do not identify the treating networks, individual clinicians or the pharmacy responsible for every GLP-1 prescription. A return address names Boudreaux’s New Drug Store at 404 East Prien Lake Road in Lake Charles, Louisiana, but that does not establish that it dispenses all advertised medication. Ask for the actual dispensing pharmacy and responsible clinical practice before proceeding, especially if a concern may need to move between customer service, the prescriber and the pharmacist.
There is a documented pharmacy-choice provision: patients may request that a prescription go to a pharmacy of their choosing by emailing service@ourviewhealth.com before completing the order. The terms do not establish that the advertised bundled price, free shipping or other arrangements follow a transferred prescription. Our guide to platform, clinician and pharmacy responsibilities can help organize those questions. Confirm the financial consequences of changing pharmacy channels before ordering, rather than assuming the preferred-pharmacy offer transfers unchanged.
Shipping promises do not settle delivery disputes
OurView advertises home delivery, discreet packaging and fast shipping, in addition to the free-shipping statements attached to its GLP-1 prices. It does not give a numerical delivery window or separate deadlines for clinical review, pharmacy preparation and transit. Because the final-sale clause turns on carrier handoff, not arrival, a patient may reach that contractual boundary before receiving the package. The documentation also does not specify shipping-storage requirements for each advertised preparation.
For medication damaged on arrival or lost in transit, the policy directs patients to the care team. For lost packages, OurView says it will first work with the carrier to locate and, where appropriate, redirect the shipment, and will reship the order if it is lost. That is a more specific commitment than the damaged-medication language, which does not state whether the remedy is replacement, refund or another resolution, or give a resolution deadline.
The policy attributes its prescription-return restriction to state and federal rules; this review does not independently establish that legal explanation. Separately, OurView may accept unopened nonprescription returns within 30 days after sale, with return shipping paid by the patient and no COD returns. That policy is not a 30-day medication guarantee. For injectable GLP-1 products arriving warm or insufficiently refrigerated, FDA explicitly advises not using the product and contacting the provider or dispensing pharmacy.
Included support needs an operational definition
OurView advertises ongoing dosage adjustments as the patient’s response changes, with no extra charge and no extra appointments for those adjustments. It also says its clinical team is available for medication and progress questions. Those are useful descriptions of intended support, but they do not establish consultation format, scheduled follow-up frequency, staffed hours or response-time commitments. They also should not be expanded into a promise that every possible clinical service or test is included.
For order or product issues, the published contacts are service@ourviewhealth.com and (573) 685-6155. The portal is the documented route for payment-method changes, address changes and subscription cancellation before shipment. A practical preparation step is to ask which channel handles symptoms, pharmacy questions and billing disputes, and how an unanswered request escalates. The public documentation does not establish that an order-support representative is also the treating clinician or an immediately available pharmacist.
OurView describes SMS medication notifications, prescription updates, refill reminders and health-related alerts. Texting “STOP” unsubscribes from that messaging service; it is not documented as canceling treatment or future charges. The terms also warn that text and email are not secure and could be read by unauthorized parties. Patients should distinguish administrative messaging from the channel intended for sensitive clinical information, while confirming how they will receive essential order updates after opting out of texts.
Insurance and dispute provisions deserve separate attention
OurView’s terms say the services are not health insurance benefits or policies and do not replace insurance. More consequentially, ordering requires agreement not to submit claims for the telemedicine services to Medicare, another federal payer, or a state or private payer. That is broader than merely saying the platform does not bill insurance. However, it concerns telemedicine services; the consulted documentation does not settle medication coverage, medication claim submission or HSA/FSA acceptance.
The dispute language also warrants clarification before enrollment. One provision requires binding arbitration in San Diego under JAMS procedures and says the arbitrator will apply California law. The general governing-law clause instead names Georgia. This review cannot determine the legal effect or enforceability of that combination. It is a documentary inconsistency to raise with OurView, not a basis for declaring either provision invalid or predicting how an actual dispute would be resolved.
Product clarity belongs in the agreement too
Both advertised GLP-1 offers are compounded preparations. FDA approval applies to a specific drug product, not to a platform or pharmacy; compounded preparations are not FDA approved and do not receive FDA premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. That recommendation is not a provider-specific endorsement.
OurView’s educational discussion mentions oral tablets and sublingual formulations as possibilities to discuss, but it does not confirm that either is sold in the priced plans. The missing route, presentation and concentration therefore matter to informed enrollment, not just product comparison. Ask for a written description of exactly what would be dispensed and who supplies instructions. Our guide to written GLP-1 quotes helps connect those details to the payment and cancellation terms without treating an educational article as a product catalog.
Questions & answers
Can I actually pay OurView monthly?
Yes. The published choices are $109 monthly for compounded semaglutide or $129 monthly for compounded tirzepatide. The $99 and $119 monthly equivalents require paying $297 or $357, respectively, upfront for three months. The pages do not fully explain subsequent billing dates or automatic renewal mechanics, so confirm those before choosing either payment interval.
Will canceling return my unused quarterly payment?
The consulted policy does not answer that clearly. It provides portal cancellation before shipment and makes sales final after charging and carrier handoff, but does not specify how an unused quarterly balance is treated. Request a written answer covering partial dispensing and partial shipment, rather than relying on the broader “Cancel anytime” language.
What happens if OurView’s clinician does not prescribe?
OurView expressly says payment does not guarantee a prescription will be written or dispensed, and its terms preserve the provider’s discretion to decline care. The public documentation reviewed does not specify the applicable refund in that situation. Before payment, ask whether any amount is retained, what event triggers a refund and how that decision is communicated.
Can I use my own pharmacy?
The terms permit directing the prescription to a pharmacy of your choice and instruct patients to email service@ourviewhealth.com before completing an order. They do not confirm that the advertised medication price or shipping arrangement applies through another pharmacy. Obtain the revised service and medication charges, and confirm that pharmacy’s ability to fill the prescription, before proceeding.
Does free shipping include a guaranteed arrival date?
No numerical arrival guarantee was established by the consulted pages. OurView advertises free and fast shipping, but does not provide a delivery timetable. For a lost shipment, it says it will investigate with the carrier before reshipping. For damage, contact the care team; the policy does not state a specific replacement or refund remedy.
Does replying STOP end my OurView subscription?
No such treatment-cancellation function is documented. “STOP” ends the SMS service, which includes prescription updates and refill reminders. The published subscription-cancellation route is the patient portal before products ship. If you want to stop future treatment charges, use that route and retain confirmation rather than assuming a text-message opt-out changes the paid subscription.
Our assessment
OurView provides useful price transparency: two named compounded medications, genuine monthly payment alternatives, explicit quarterly prepayment amounts, free shipping and no advertised membership fee. It also documents a cancellation portal, pharmacy-choice request and lost-package process. The contract weakness is the space between those promises: renewal mechanics, unused quarterly balances, denied-prescription refunds and damaged-product remedies remain unclear. Its platform model also makes identifying the responsible clinician and dispensing pharmacy important. Before enrolling, obtain written answers tied to the selected payment plan and actual product. The documentation supports evaluating OurView as an available GLP-1 platform, but not treating “Cancel anytime” as a refund guarantee or its commercial claims as proof of clinical outcomes.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.